[
  {
    "ts": "2025-11-20T12:30:00+00:00",
    "headline": "Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference",
    "summary": "New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th",
    "url": "https://finance.yahoo.com/news/biogen-highlight-lecanemab-data-scientific-123000733.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b7f9605c-c198-3396-b705-a8ee9f4dfbff",
      "content": {
        "id": "b7f9605c-c198-3396-b705-a8ee9f4dfbff",
        "contentType": "STORY",
        "title": "Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference",
        "description": "",
        "summary": "New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th",
        "pubDate": "2025-11-20T12:30:00Z",
        "displayTime": "2025-11-20T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-highlight-lecanemab-data-scientific-123000733.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-highlight-lecanemab-data-scientific-123000733.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]